ResMed Inc. (RMD)
Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care
RMD's MatrixCare sale sharpens its focus on sleep, breathing and connected care while freeing resources for AI-powered digital health.
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ResMed to sell software business MatrixCare for $490 million
ResMed said on Tuesday it would sell its software business MatrixCare to private equity firm Frazier Healthcare Partners for $490 million in cash, as the health technology company sharpens its focus on sleep, breathing and home-based care.
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ResMed (RMD) Soars 4.2%: Is Further Upside Left in the Stock?
ResMed (RMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Here's Why ResMed (RMD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ResMed (RMD) Upgraded to Buy: Here's Why
ResMed (RMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think ResMed (RMD) Could Surge 28.21%: Read This Before Placing a Bet
The mean of analysts' price targets for ResMed (RMD) points to a 28.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ResMed: Fear-Driven Selloff Creates A Compelling Margin Of Safety Entry Point
ResMed (RMD) exemplifies the razor-and-blade model, leveraging inevitability, brand loyalty, inexpensive recurring costs, and a superior user experience. RMD dominates the sleep apnea market with a 62% share in a vast, under-penetrated addressable market with huge future growth potential. RMD's financials are resilient, with consistent sales and earnings growth, no earnings misses in more than a decade, and a predictable business model.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ResMed: GLP-1 Threats Are Overstated
My contrarian take on ResMed is that GLP-1 concerns are overstated, and even though a portion of market share will be lost, the remaining portion will be more beneficial to profitability. Other business threats come from PHG's reentrance and Apnimed's drug commercialization. While not to be overlooked, I still see RMD retaining its market dominance. The stock currently trades as if revenues are already declining and margins are contracting. But the opposite is true. Margins far exceed peers, and the top line grows at double digits.
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
RMD gains from acquisition-led Residential Care Software growth, mask innovation and strong finances but faces macro and competitive pressures.
